Sajid, et al., published in the journal Science Translational Medicine about the development of a promising mRNA vaccine, 19ISP, which has been found to induce tick resistance and prevent transmission of the Lyme disease-causing agent, Borrelia burgdorferi (Bb).
This Lyme Disease Association website Vaccine page begins with a series of current articles on Lyme disease vaccine efforts and pertinent vaccine peer review articles. Scrolling down, the pages continue to go backward in time to the history of early Lyme disease vaccines and the controversy which surrounded the vaccine trials and the subsequent LymeRix FDA approval, and then the withdrawal from the market of that vaccine.
The National Institute of Allergy & Infectious Diseases (NIAID), National Institutes of Health (NIH), has a page on Lyme vaccines including its information on what occurred with the first Lyme vaccine, LYMErix, and what is happening with some current vaccines and vaccine research. https://www.niaid.nih.gov/diseases-conditions/lyme-disease-vaccines
Pfizer has received priority review for their vaccine, TicoVac, that protects against tick-borne encephalitis. This tick-borne virus can cause meningitis and trigger long-term neurological symptoms. If approved, the vaccine would potentially protect travelers as well as members of the US military that are deployed to regions where the virus is common, such as Europe and parts of Asia.
Valneva and Pfizer announced that they have initiated a Phase 2 study for their Lyme disease vaccine candidate. This new study builds on previous studies, including new dose regimens as well as being the first clinical study to include children between the ages 5-17 years.
West Virginia University researchers received a $1.9 million grant from the National Institute of Allergy and Infectious Diseases, an institution of the National Institute of Health (NIH), for a vaccine to prevent humans from contracting Lyme disease. Mariette Barbier, assistant professor in the School of Medicine’s Department of Microbiology, Immunology and Cell Biology, is leading […]
With a new $3.5 million grant from the National Institutes of Health (NIH), Utpal Pal, PhD, professor in Veterinary Medicine at the University of Maryland (UMD) will be partnering with Matthias Schnell, director of the Jefferson Vaccine Center at Thomas Jefferson University to develop a novel “next-generation” Lyme disease vaccine. Pal, a tick immunobiologist, and […]
Valneva announced that the vaccine candidate against Lyme disease, VLA15-201, showed positive initial results meeting its endpoints in the Phase 2 study. They stated in the July 22, 2020 press release that “compared to Phase 1, the higher doses used in this trial elicited higher antibody responses across all serotypes.” Of particular note was the […]
An article on a new vaccine for Lyme disease, “New Effort for Lyme Disease Vaccine Draws Early Fire,” by Sumathi Reddy, appeared in the Wall Street Journal on July 9, 2018. The article, which includes a quote by LDA President, Pat Smith, reports that a European company, Valneva SE, is in clinical trials for a […]
This is a piece on the Lymerix Vaccine controversy, written by Patricia V. Smith, President, Lyme Disease Association, Inc., in 2013 and published on LDA website. 2013 version published on LDA website It was published in the Lyme Times Special Issue Sept. 2018 The LYMErix™ Story: FDA Approval to Market Withdrawal ─ Learning from History […]